![Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The](https://www.thelancet.com/cms/attachment/22718fe8-5fbf-4f23-885a-99f477472003/gr2.jpg)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-018-0360-y/MediaObjects/41416_2018_360_Fig1_HTML.png)
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/RCT-of-Letrozole-in-Post-menopausal-breast-cancer.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Definition of progression free survival and overall survival for the... | Download Scientific Diagram Definition of progression free survival and overall survival for the... | Download Scientific Diagram](https://www.researchgate.net/publication/265644752/figure/fig1/AS:269802786783234@1441337405030/Definition-of-progression-free-survival-and-overall-survival-for-the-Gold-standard-and.png)
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure2-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab](https://www.mdpi.com/cancers/cancers-12-03021/article_deploy/html/images/cancers-12-03021-g001-550.jpg)
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
![Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1526820916303585-gr2.jpg)
Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect
![Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive](https://archive.cancerworld.net/wp-content/uploads/2015/10/Correlation-by-itself-does-not-imply-surrogacy.jpg)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
![Progression free survival and overall survival in patients treated with... | Download Scientific Diagram Progression free survival and overall survival in patients treated with... | Download Scientific Diagram](https://www.researchgate.net/publication/320272594/figure/fig3/AS:547183110098944@1507470027498/Progression-free-survival-and-overall-survival-in-patients-treated-with-nivolumab-based.png)
Progression free survival and overall survival in patients treated with... | Download Scientific Diagram
![Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086418309353-gr1.jpg)
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fbjc.2016.83/MediaObjects/41416_2016_Article_BFbjc201683_Fig2_HTML.jpg)
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy | British Journal of Cancer
How do doctors interpret differences between overall survival and progression free survival? - Quora
![Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram](https://www.researchgate.net/publication/306551418/figure/fig3/AS:567236567855104@1512251144196/Progression-free-survival-PFS-A-and-overall-survival-OS-B-based-on-disease-free.png)
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
![Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic](https://d3i71xaburhd42.cloudfront.net/2aa8254fae649d2ab35d92abb79d94fa9d17f39e/4-Figure1-1.png)
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)